← Back to Clinical Trials
Recruiting NCT07125001

NCT07125001 Mango Intake and Gut and Cardiometabolic Health in Hispanic/Latino Adolescents

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07125001
Status Recruiting
Phase
Sponsor University of California, Davis
Condition Cardiometabolic Health Indicators
Study Type INTERVENTIONAL
Enrollment 25 participants
Start Date 2025-10-01
Primary Completion 2028-03-31

Eligibility & Interventions

Sex All sexes
Min Age 12 Years
Max Age 19 Years
Study Type INTERVENTIONAL
Interventions
Ataulfo mango

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 25 participants in total. It began in 2025-10-01 with a primary completion date of 2028-03-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Mangos contain a number of nutrients that may improve gut and metabolic health. The purpose of this research is to see how eating mangos every day for 4 weeks instead of snacks high in calories and low in nutrients such as cookies, crackers, chips, and candy can impact adolescent health.

Eligibility Criteria

Inclusion Criteria: * \- Male or Female 12-19 years old * BMI ≥ 85th percentile (https://www.bcm.edu/bodycomplab/BMIapp/BMI-calculator-kids.html) * Self-reported Hispanic/Latino * Subject is willing and able to comply with the study protocols * Subject is willing to consume the test products * Female-specific criteria: if menstruating, eumenorrheic (regular monthly menstrual cycles of 25-30-days in length) * Access to a smartphone or tablet at least 1x / day and willing to take pictures associated with the products to be consumed in the study Exclusion Criteria: * \- Reported food allergies. * Currently taking prescription drugs, with the exception of asthma inhalers, which are allowed * BMI \<85th percentile (https://www.bcm.edu/bodycomplab/BMIapp/BMI-calculator-kids.html) * Current participation in a moderate or high-intensity daily exercise routine * Self-reported disease, serious illness, or who are currently under acute medical care. * Currently taking prescription drugs. * Any supplement use, including multi-vitamin/ mineral, herbal, plant or botanical, fish oil, and oil supplements, and not willing to discontinue before starting the study. * Vegetarian or vegan diet * Self-reported malabsorption or gastrointestinal issues * Fruit and vegetable intake exceeding daily recommendations of 5 servings * Smoking (vaping, conventional nicotine-containing products or marijuana) * Current enrollee in a clinical research study

Contact & Investigator

Central Contact

Roberta R Holt, PhD

✉ rrholt@ucdavis.edu

📞 15304005952

Principal Investigator

Roberta R Holt, PhD

PRINCIPAL INVESTIGATOR

University of California, Davis

Frequently Asked Questions

Who can join the NCT07125001 clinical trial?

This trial is open to participants of all sexes, aged 12 Years or older, up to 19 Years, studying Cardiometabolic Health Indicators. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07125001 currently recruiting?

Yes, NCT07125001 is actively recruiting participants. Contact the research team at rrholt@ucdavis.edu for enrollment information.

Where is the NCT07125001 trial being conducted?

This trial is being conducted at Davis, United States.

Who is sponsoring the NCT07125001 clinical trial?

NCT07125001 is sponsored by University of California, Davis. The principal investigator is Roberta R Holt, PhD at University of California, Davis. The trial plans to enroll 25 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology